Medacta Group (MOVE.SW) Stock Price

Medacta Group Price

SIX·CLOSED
139.00EUR-2.14 (-1.53 %)
Market closed

Over the last 9 years Medacta Group grew revenue by 13.5% annually, reaching 634.46 M EUR. Earnings per share have grown at 10.4% per year over the last 9 years. For Medacta Group, the net margin of 14.1% is broadly stable versus 14.4% a few years ago. At today's price the dividend yield works out to roughly 0.25%. The payout ratio is around 8% of earnings. The dividend has grown at 8.8% per year over the past 3 years. The consensus 12-month price target for Medacta Group is 176.02 EUR, about 26.6% above where the stock trades today. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.

Medacta Group stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Medacta Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Medacta Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Medacta Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Medacta Group Stock Price History
DateMedacta Group Price
8/6/2026139.00 EUR
8/5/2026141.14 EUR
8/4/2026143.17 EUR
7/31/2026141.44 EUR
7/30/2026147.79 EUR
7/29/2026147.79 EUR
7/28/2026143.15 EUR
7/27/2026142.72 EUR
7/24/2026140.19 EUR
7/23/2026140.75 EUR
7/22/2026140.53 EUR
7/21/2026141.36 EUR
7/20/2026143.55 EUR
7/17/2026149.85 EUR
7/16/2026151.36 EUR
7/15/2026148.94 EUR
7/14/2026149.08 EUR
7/13/2026151.51 EUR
7/10/2026151.68 EUR
7/9/2026148.36 EUR
7/8/2026148.13 EUR
7/7/2026151.00 EUR
7/6/2026154.06 EUR
7/3/2026146.05 EUR
7/2/2026146.27 EUR
7/1/2026144.80 EUR
6/30/2026147.48 EUR
6/29/2026148.16 EUR
6/26/2026147.01 EUR
6/25/2026148.79 EUR
6/24/2026148.12 EUR
6/23/2026143.75 EUR
6/22/2026144.19 EUR
6/19/2026146.75 EUR
6/18/2026144.80 EUR
6/17/2026146.14 EUR
6/16/2026145.42 EUR
6/15/2026149.06 EUR
6/12/2026147.81 EUR
6/11/2026148.68 EUR
6/10/2026150.39 EUR
6/9/2026149.74 EUR
6/8/2026150.18 EUR
6/5/2026151.86 EUR
6/4/2026149.16 EUR
6/3/2026148.29 EUR
6/2/2026151.48 EUR
6/1/2026153.14 EUR
5/29/2026154.05 EUR
5/28/2026153.90 EUR
5/27/2026160.86 EUR
5/26/2026158.90 EUR
5/22/2026157.50 EUR
5/21/2026162.05 EUR
5/20/2026159.37 EUR
5/19/2026158.06 EUR
5/18/2026151.29 EUR
5/15/2026151.08 EUR
5/13/2026147.71 EUR
5/12/2026147.49 EUR
5/11/2026146.40 EUR
5/8/2026149.68 EUR
5/7/2026152.73 EUR
5/6/2026156.66 EUR
5/5/2026153.60 EUR
5/4/2026154.48 EUR
4/30/2026154.48 EUR
4/29/2026156.00 EUR
4/28/2026159.28 EUR
4/27/2026161.90 EUR
4/24/2026161.68 EUR
4/23/2026163.86 EUR
4/22/2026169.31 EUR
4/21/2026170.40 EUR
4/20/2026174.33 EUR
4/17/2026178.04 EUR
4/16/2026172.59 EUR
4/15/2026174.77 EUR
4/14/2026170.40 EUR
4/13/2026167.57 EUR
4/10/2026167.35 EUR
4/9/2026163.20 EUR
4/8/2026165.17 EUR
4/7/2026167.04 EUR
4/2/2026165.16 EUR
3/27/2026163.20 EUR
3/26/2026161.40 EUR
3/25/2026161.84 EUR
3/24/2026161.08 EUR
3/23/2026163.75 EUR
3/20/2026171.65 EUR
3/19/2026172.11 EUR
3/17/2026176.38 EUR
3/16/2026175.89 EUR
3/13/2026172.49 EUR
3/12/2026168.62 EUR
3/11/2026169.16 EUR
3/10/2026173.93 EUR
3/9/2026168.87 EUR
3/6/2026173.40 EUR
3/5/2026172.89 EUR
2/27/2026175.41 EUR
2/26/2026174.71 EUR
2/25/2026169.68 EUR
2/23/2026165.47 EUR
2/20/2026166.44 EUR
2/19/2026166.64 EUR
2/18/2026164.95 EUR
2/17/2026162.93 EUR
2/16/2026162.16 EUR
2/13/2026162.97 EUR
2/12/2026162.50 EUR
2/11/2026166.03 EUR
2/10/2026168.09 EUR
2/9/2026167.79 EUR
2/6/2026166.94 EUR
2/5/2026169.67 EUR
2/4/2026169.78 EUR
2/3/2026177.55 EUR
2/2/2026182.27 EUR
1/30/2026182.01 EUR
1/29/2026185.19 EUR
1/28/2026185.72 EUR
1/27/2026184.53 EUR
1/26/2026189.31 EUR
1/23/2026188.88 EUR
1/22/2026189.15 EUR
1/21/2026183.56 EUR
1/20/2026184.89 EUR
1/19/2026175.53 EUR
1/16/2026176.71 EUR
1/15/2026175.59 EUR
1/14/2026177.82 EUR
1/13/2026177.51 EUR
1/12/2026177.66 EUR
1/9/2026180.41 EUR
1/8/2026181.80 EUR
1/7/2026182.70 EUR
1/6/2026173.71 EUR
1/5/2026168.57 EUR
12/30/2025168.06 EUR
12/29/2025167.86 EUR
12/24/2025165.00 EUR
12/23/2025165.12 EUR
12/22/2025164.04 EUR
12/19/2025162.95 EUR
12/18/2025163.03 EUR
12/17/2025161.79 EUR
12/16/2025163.02 EUR
12/15/2025162.35 EUR
12/12/2025161.97 EUR
12/11/2025162.70 EUR
12/10/2025162.26 EUR
12/9/2025161.60 EUR
12/8/2025160.36 EUR
12/5/2025161.95 EUR
12/4/2025162.75 EUR
12/3/2025160.90 EUR
12/2/2025161.67 EUR
12/1/2025164.97 EUR
11/28/2025165.90 EUR
11/27/2025167.74 EUR
11/26/2025166.15 EUR
11/25/2025165.88 EUR
11/24/2025164.92 EUR
11/21/2025161.69 EUR
11/20/2025163.45 EUR
11/19/2025161.83 EUR
11/18/2025160.65 EUR
11/17/2025163.40 EUR
11/14/2025165.20 EUR
11/13/2025166.96 EUR
11/12/2025164.49 EUR
11/11/2025161.19 EUR
11/10/2025155.72 EUR
11/7/2025150.59 EUR
11/6/2025152.61 EUR
11/5/2025154.71 EUR
11/4/2025159.37 EUR
11/3/2025160.58 EUR
10/31/2025159.23 EUR
10/30/2025159.45 EUR
10/29/2025158.79 EUR
10/28/2025159.47 EUR
10/27/2025160.87 EUR
10/24/2025161.92 EUR
10/23/2025162.64 EUR
10/22/2025162.14 EUR
10/21/2025161.57 EUR
10/20/2025160.15 EUR
10/17/2025157.78 EUR
10/16/2025160.81 EUR
10/15/2025158.53 EUR
10/14/2025157.53 EUR
10/13/2025159.38 EUR
10/10/2025161.23 EUR
10/9/2025161.75 EUR
10/8/2025160.49 EUR
10/7/2025155.73 EUR
10/6/2025155.91 EUR
10/3/2025155.16 EUR
10/2/2025153.22 EUR
10/1/2025152.81 EUR
9/29/2025156.02 EUR
9/26/2025156.17 EUR
9/25/2025157.67 EUR
9/24/2025163.68 EUR
9/23/2025163.85 EUR
9/22/2025165.04 EUR
9/19/2025164.08 EUR
9/18/2025166.72 EUR
9/17/2025164.86 EUR
9/16/2025164.22 EUR
9/15/2025162.50 EUR
9/12/2025160.79 EUR
9/11/2025160.02 EUR
9/10/2025161.56 EUR
9/9/2025159.68 EUR
9/8/2025157.32 EUR
9/5/2025151.70 EUR
9/4/2025152.07 EUR
9/3/2025152.54 EUR
9/2/2025153.57 EUR
9/1/2025159.44 EUR
8/29/2025155.08 EUR
8/28/2025153.71 EUR
8/27/2025156.12 EUR
8/26/2025157.63 EUR
8/25/2025156.54 EUR
8/22/2025156.58 EUR
8/21/2025160.69 EUR
8/20/2025163.92 EUR
8/19/2025163.52 EUR
8/18/2025163.07 EUR
8/15/2025162.92 EUR
8/14/2025161.45 EUR
8/13/2025162.74 EUR
8/12/2025164.71 EUR
8/11/2025156.55 EUR
8/8/2025156.45 EUR
8/7/2025159.75 EUR
8/6/2025160.50 EUR
Access this data via the Eulerpool API
Get Free API Key

Medacta Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
469.19 M EUR
69.31 M EUR
44.10 M EUR
Jan 1, 2024
542.85 M EUR
84.57 M EUR
67.86 M EUR
Jan 1, 2025
634.46 M EUR
107.67 M EUR
89.49 M EUR
Jan 1, 2026 (e)
711.73 M EUR
125.05 M EUR
103.93 M EUR
Jan 1, 2027 (e)
798.45 M EUR
140.34 M EUR
119.09 M EUR
Jan 1, 2028 (e)
948.31 M EUR
156.05 M EUR
138.41 M EUR
Jan 1, 2029 (e)
1.04 B EUR
171.69 M EUR
163.57 M EUR
Jan 1, 2030 (e)
1.12 B EUR
184.44 M EUR
189.36 M EUR

Medacta Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 3:23 PM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.200.230.250.290.280.340.410.480.550.640.710.800.951.041.12
–11.8211.4514.23-2.7720.2820.1217.0015.5816.5811.0912.2418.8010.027.38
75.3774.8974.7071.9770.8271.8969.9568.0067.5864.0664.0664.0664.0664.0664.06
153.00170.00189.00208.00199.00243.00284.00323.00371.00410.00455.48511.22607.31668.17717.50
46.0046.0057.0037.0046.0054.0057.0069.0084.00107.00125.00140.00156.00171.00184.00
22.6620.2622.5312.8016.3715.9814.0414.5315.3016.7217.5817.5416.4616.4016.43
36.0031.0042.0011.0034.0047.0043.0044.0067.0089.00103.00119.00138.00163.00189.00
–-13.8935.48-73.81209.0938.24-8.512.3352.2732.8415.7315.5315.9718.1215.95
––––––0.270.270.280.350.380.410.44––
––––––––3.7021.4311.767.897.32––
20.0020.0020.0020.0020.0020.0120.0019.9919.9420.1220.1220.1220.1220.1220.12
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Medacta Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Medacta Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Medacta Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Medacta Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Medacta Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Medacta Group stock margins

The Medacta Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medacta Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medacta Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
73.24 %
16.48 %
14.44 %
Jan 1, 2022
70.42 %
14.18 %
10.67 %
Jan 1, 2023
69.02 %
14.77 %
9.40 %
Jan 1, 2024
68.51 %
15.58 %
12.50 %
Jan 1, 2025
64.77 %
16.97 %
14.11 %
Jan 1, 2026 (e)
64.77 %
17.57 %
14.60 %
Jan 1, 2027 (e)
64.77 %
17.58 %
14.91 %
Jan 1, 2028 (e)
64.77 %
16.46 %
14.60 %

Medacta Group Stock Revenue, EBIT, Earnings per Share

The Medacta Group earnings per share therefore indicates how much revenue Medacta Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
16.60 EUR
2.74 EUR
2.40 EUR
Jan 1, 2022
20.18 EUR
2.86 EUR
2.15 EUR
Jan 1, 2023
23.47 EUR
3.47 EUR
2.21 EUR
Jan 1, 2024
27.22 EUR
4.24 EUR
3.40 EUR
Jan 1, 2025
31.53 EUR
5.35 EUR
4.45 EUR
Jan 1, 2026 (e)
35.64 EUR
6.21 EUR
5.20 EUR
Jan 1, 2027 (e)
39.98 EUR
6.97 EUR
5.96 EUR
Jan 1, 2028 (e)
47.48 EUR
7.76 EUR
6.93 EUR

Medacta Group business model & stock analysis

The Medacta Group SA is a leading global company in the development, manufacturing, and marketing of medical devices and implants for the orthopedic industry. The company was founded in 1999 by Swiss entrepreneur Alberto Siccardi and is headquartered in Switzerland. The Medacta Group SA has its origins in one person - Alberto Siccardi. As a former athlete and successful entrepreneur, he had a vision that he put into action. He founded the Medacta Group and began focusing on the development and manufacturing of innovative orthopedic devices and implants. The Medacta Group has an innovative business model because the company is able to handle everything from research and development to marketing and sales of its products. This means that Medacta combines all steps from idea to end product under one roof and has complete control over the entire process. The Medacta Group SA is divided into three business areas: orthopedics, spine, and sports medicine. In the orthopedic field, the company manufactures hip and knee joint implants, as well as shoulder and elbow implants. Medacta also offers technologies that help extend the lifespan of artificial joints. In the spine field, the company provides instruments and implants for spine surgery. Medacta has a high level of expertise in this field and is known for innovative products that contribute to improving patient treatment. In the sports medicine field, the Medacta Group offers solutions for sports injuries. The company has developed a wide range of technologies and products that accelerate the healing process and support rehabilitation. Some of Medacta's most well-known products are the AMIS (Anterior Minimally Invasive Surgery) hip joint system and the GMK (General Medacta Knee) knee joint system. The AMIS system is a minimally invasive procedure for hip joint surgery that aims to shorten rehabilitation time and reduce the risk of complications. The GMK system is an innovative knee joint system that allows natural joint mechanics and approximates the natural knee pivot point. Medacta has also developed a range of software solutions that support surgeons in the planning and execution of operations. These solutions provide detailed visualizations and allow for precise planning of procedures. In conclusion, the Medacta Group SA is a global leader in the development and manufacturing of medical devices and implants for orthopedics, spine, and sports medicine. The company has an innovative business model that allows for complete control of the entire manufacturing process. Through the development of innovative products and technologies, the Medacta Group supports the treatment and rehabilitation of patients worldwide.

Medacta Group SWOT Analysis

Strengths

Medacta Group SA has several strengths that contribute to its success in the market. Firstly, the company possesses a strong reputation for its innovative medical devices and solutions. This reputation has been built through years of research and development, leading to high-quality products. Additionally, Medacta Group SA has established strong relationships with healthcare professionals and institutions globally, which allows for widespread distribution and adoption of its products.

Weaknesses

Despite its strengths, Medacta Group SA also faces certain weaknesses that need to be addressed. One major weakness is the company's limited geographic presence compared to some of its competitors. Medacta Group SA primarily operates in Europe and Asia, which limits its market reach and potential for growth in other regions. Another weakness is the company's heavy reliance on a few key products for its revenue. This lack of diversification exposes Medacta Group SA to potential market volatility and competitive threats in the long term.

Opportunities

There are several opportunities that Medacta Group SA can capitalize on to further enhance its market position. Firstly, the growing global demand for minimally invasive surgical procedures presents a significant opportunity for Medacta Group SA's innovative medical devices. By continuing to invest in research and development, the company can develop new products that cater to this trend and gain a competitive edge. Additionally, expanding into untapped markets such as North America and Latin America can help Medacta Group SA diversify its revenue streams and reduce its dependence on specific regions.

Threats

Despite the opportunities, Medacta Group SA faces several threats that may hinder its growth and profitability. One major threat is intense competition in the medical device industry. Competitors with larger market shares and broader product portfolios pose a challenge to Medacta Group SA's market position. Additionally, stringent regulatory requirements and the need for rigorous clinical trials can increase the time and cost of bringing new products to market, potentially impacting Medacta Group SA's ability to stay ahead of the competition. Lastly, economic downturns and healthcare budget constraints in key markets can reduce the demand for medical devices, affecting Medacta Group SA's sales and profitability.

Medacta Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Medacta Group historical P/E ratio, EBIT multiple, and P/S ratio

Medacta Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Medacta Group shares outstanding

The number of shares of Medacta Group was 20.12 M in 2025. This indicates how many shares Medacta Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
20.01 M Stocks
Jan 1, 2022
20.00 M Stocks
Jan 1, 2023
19.99 M Stocks
Jan 1, 2024
19.94 M Stocks
Jan 1, 2025
20.12 M Stocks
Jan 1, 2026 (e)
20.12 M Stocks
Jan 1, 2027 (e)
20.12 M Stocks
Jan 1, 2028 (e)
20.12 M Stocks

Medacta Group Dividend History

4 years of dividend payments · 3 consecutive increases

YearAnnual DividendYoY ChangePayments
20250.35EUR↑ 25.5%1×
May 9, 20250.35EUR↑ 25.5%1/1
20240.28EUR↑ 1.9%1×
20230.27EUR↑ 0.9%1×
20220.27EUR—1×

Medacta Group dividend history and estimates

In 2025, Medacta Group paid a dividend amounting to 0.35 EUR. Dividend means that Medacta Group distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2022
0.27 EUR
0.00 EUR
Jan 1, 2023
0.27 EUR
0.00 EUR
Jan 1, 2024
0.28 EUR
0.00 EUR
Jan 1, 2025
0.35 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
0.38 EUR
Jan 1, 2027 (e)
0.00 EUR
0.41 EUR
Jan 1, 2028 (e)
0.00 EUR
0.44 EUR

Medacta Group dividend payout ratio

In 2025, Medacta Group had a payout ratio of 8.31%. The payout ratio indicates the percentage of the company's profits that Medacta Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
10.03 %
Jan 1, 2022
13.33 %
Jan 1, 2023
13.12 %
Jan 1, 2024
8.66 %
Jan 1, 2025
8.31 %
Jan 1, 2026 (e)
7.21 %
Jan 1, 2027 (e)
6.85 %
Jan 1, 2028 (e)
6.42 %

Current Medacta Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
81.82 % (9)
Hold
18.18 % (2)
Sell
0.00 % (0)
12M Price Target
0.00
Last Price
141.14
Currency
EUR
12M Return Potential
-100.00 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Medacta Group stock

81/100
99
Environment
99
Social
45
Governance
E

Environment

20
Scope 1 - Direct Emissions1,296
Scope 2 - Indirect emissions from purchased energy620
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions1,916
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees32
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Medacta Group shareholder structure

% Name
1.06094%
GAM Investment Management (Switzerland) AG
GAM Investment Management (Switzerland) AG
0.97655%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.65519%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.65089%
SEB Asset Management (Denmark)
SEB Asset Management (Denmark)
0.58281%
UBS Asset Management (Switzerland)
UBS Asset Management (Switzerland)
0.55016%
Florida State Board of Administration
Florida State Board of Administration
...

Medacta Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
30.1%
Float Shares
-
Shares Outstanding
-

Medacta Group Executives and Management Board

9 members · avg. age 58 · 11 % women

FS

Mr. Francesco Siccardi (47)

Chief Executive Officer, Member of the Group Executive Management

1.88 M EUR

Management

CF

Mr. Corrado Farsetta (56)

Chief Financial Officer, Member of the Group Executive Management

–
SR

Mr. Strada Regina

IR Contact Officer · since 2022

–

Board of Directors

AS

Mr. Alberto Siccardi (80)

Non-Executive Chairman of the Board

325,638.00 EUR
VB

Mr. Victor Balli (68)

Non-Executive Lead Independent Director

214,599.00 EUR
PW

Mr. Philippe Weber (59)

Non-Executive Independent Director

141,250.00 EUR
MT

Mrs. Maria Siccardi Tonolli (49)

Non-Executive Director

127,795.00 EUR
RB

Mr. Riccardo Braglia (64)

Non-Executive Independent Director

119,519.00 EUR
AS

Mr. Alessandro Siccardi (38)

Supply Chain Director, Member of the Group Executive Management

–

Frequently asked questions about Medacta Group

Medacta Group SA operates under a medical technology business model. As a leading manufacturer in the orthopedic industry, Medacta specializes in designing, developing, and distributing innovative surgical solutions. The company is primarily focused on providing integrated solutions for joint replacement, spine surgery, and sports medicine. Medacta aims to improve patient outcomes by offering a comprehensive range of products, including implants, instruments, and computer-assisted technologies. With a commitment to research and development, Medacta continuously pushes the boundaries of medical technology, enabling healthcare professionals to deliver advanced and personalized care to patients worldwide.

Medacta Group SA is primarily active in the medical industry. As an innovative medical device company, Medacta specializes in developing and manufacturing orthopedic implants and surgical instruments. With a focus on personalized solutions, the company offers products for various medical procedures, including joint replacement, spine surgery, and sports medicine. Leveraging advanced technologies and research expertise, Medacta aims to improve patient outcomes and enhance surgical techniques. With its unwavering commitment to innovation and quality, Medacta Group SA has established itself as a prominent player in the medical field.

The main competitors of Medacta Group SA in the market are other companies in the orthopedic medical device industry, such as Zimmer Biomet Holdings Inc., Stryker Corporation, and Johnson & Johnson. These companies also specialize in producing and marketing orthopedic implants and surgical instruments. Medacta Group SA faces competition from these established players, but it differentiates itself through its innovative product offerings, strong focus on customer satisfaction, and dedication to continuous research and development. Its commitment to providing high-quality orthopedic solutions positions Medacta Group SA as a leading player in the market.

Medacta Group SA is a leading Swiss medical device company specializing in orthopedic products and services. Founded in 1999 by Dr. Alberto Siccardi, Medacta has grown to become a trusted player in the global healthcare industry. The company focuses on developing innovative solutions for joint replacement, spine surgery, and sports medicine. With a strong commitment to research and development, Medacta has revolutionized surgical approaches and attained international recognition. Medacta's dedication to providing surgeons with state-of-the-art tools and patients with improved outcomes has led to its global success. As a reputable supplier in the medical field, Medacta Group SA continues to strive for excellence in its products and services for the benefit of patients worldwide.

Medacta Group SA has achieved several significant milestones. Firstly, the company has successfully expanded its global presence, operating in over 50 countries worldwide. Additionally, Medacta Group SA has demonstrated continuous innovation in the field of medical devices and orthopedic solutions. The company has received numerous accolades for its cutting-edge technologies and advanced research initiatives. Medacta Group SA has also shown resilience during challenging times, maintaining steady growth in revenue and market share. Overall, the company's commitment to excellence and dedication to improving patient outcomes have positioned Medacta Group SA as a trusted leader in the healthcare industry.

Medacta Group SA is primarily present in Europe, the United States, and Asia. The company has a strong presence in countries such as Switzerland, Italy, Germany, France, Spain, the United Kingdom, and the Netherlands. Additionally, Medacta Group SA has established a significant footprint in North America, with a focus on the United States. The company's presence in Asia includes countries like Japan, China, South Korea, Malaysia, and Singapore. Medacta Group SA's global presence enables it to provide its innovative medical solutions and orthopedic products to a wide range of healthcare professionals and patients around the world.

Medacta Group SA represents values of innovation, excellence, and patient-centricity in the healthcare industry. As a leading medical device company, Medacta focuses on developing and providing cutting-edge surgical solutions to enhance patient outcomes and improve the quality of life. The company's corporate philosophy revolves around collaboration, integrity, and a strong commitment to continuous improvement. Medacta strives to establish long-term partnerships with surgical teams, ensuring the highest standards of safety and efficiency. By consistently prioritizing patient well-being and leveraging its technological expertise, Medacta Group SA remains at the forefront of advancing medical advancements and delivering top-notch surgical solutions globally.

Analysts currently set an average price target of 181.05 EUR for the Medacta Group stock (median: 176.02 EUR), implying +28.3 % versus the latest price. The consensus is based on 11 analyst ratings.

Medacta Group Analyst Price Targets 2026

11 analysts currently rate the Medacta Group stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Medacta Group to generate revenue of 711.73 M EUR and earnings per share of 5.16 EUR.

Medacta Group Analyst Price Targets 2026

The Medacta Group share (MOVE.SW) is listed on 7 stock exchanges, including: Frankfurt (6MD.F), München (6MD.MU), Düsseldorf (6MD.DU), London (0A05.L), London (0A05.L), SIX (Zürich) (MOVE.SW).

Medacta Group SA is a leading medical technology company specializing in the development, production, and marketing of innovative surgical solutions. The company operates globally and offers products and services in various business areas including orthopedics, spine, robotics, and traumatology. They also have expertise in digital health, offering solutions in telemedicine, risk management, and surgical planning. Their business model focuses on continuous improvement to provide high-quality products and collaborations with medical professionals to meet their needs. Through research and development, they aim to bring innovative technologies to the healthcare industry. Overall, Medacta Group SA offers a wide range of products and services tailored to the needs of healthcare professionals and patients, establishing themselves as a leading company in the medical technology industry.

The expected revenue of Medacta Group is 711.73 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Medacta Group is 103.93 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medacta Group is currently 26.91. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medacta Group stock.

The price-to-sales ratio (P/S) of Medacta Group is currently 3.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medacta Group stock.

The Eulerpool Quality Score for Medacta Group is 6/10.

The ISIN of Medacta Group is CH0468525222. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Medacta Group is A2PFTD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Medacta Group is MOVE.SW. The ticker symbol is used to trade Medacta Group shares on the stock exchange.

Over the past 12 months, Medacta Group paid a dividend of 0.35 EUR . This corresponds to a dividend yield of about 0.25 %. For the coming 12 months, Medacta Group is expected to pay a dividend of 0.41 EUR.

The current dividend yield of Medacta Group is 0.25 %.

Medacta Group pays a dividend, distributed in the months of , , , .

Medacta Group paid dividends every year for the past 4 years.

For the upcoming 12 months, dividends amounting to 0.41 EUR are expected. This corresponds to a dividend yield of 0.29 %.

Medacta Group is assigned to the 'Health' sector.

To receive the latest dividend of Medacta Group from amounting to 0.35 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Medacta Group distributed 0.28 EUR as dividends.

The dividends of Medacta Group are distributed in EUR.

All fundamentals and in-depth analysis of Medacta Group

Our stock analysis for Medacta Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medacta Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Medacta Group Stock
Medacta Group Revenue→
Medacta Group Stock
Medacta Group Net Income→
Medacta Group Stock
Medacta Group P/E→
Medacta Group Stock
Medacta Group P/S→
Medacta Group Stock
Medacta Group EBIT→
Medacta Group Stock
Medacta Group Dividend→
Medacta Group Stock
Medacta Group Directors Dealings→
Medacta Group Stock
Medacta Group Stocks→
Medacta Group Stock
Medacta Group Market capitalization→
Medacta Group Stock
Medacta Group Debt→
Medacta Group Stock
Medacta Group Liabilities→
Medacta Group Stock
Medacta Group Equity→
Medacta Group Stock
Medacta Group AAQS→
Medacta Group Stock
Medacta Group Employees→
Medacta Group Stock
Medacta Group ROE→
Medacta Group Stock
Medacta Group ROA→
Medacta Group Stock
Medacta Group ROCE→
Medacta Group Stock
Medacta Group News→
Medacta Group Stock
Medacta Group Analyst Price Targets→

Health Stocks

MedappMeCure IndustriesMedartis HoldingMe TodayMedCap AB (publ)MDxHealthMedeon BiodesignMdwerksMedi Assist Healthcare ServicesMcKessonMedian TechnologiesMBX BiosciencesAll Stocks A–Z →